PhRMA Touts Robust Pipelines in Face of Patent Cliff Fallout

Drug company pipelines are more robust than ever, PhRMA announced Jan. 17 in releasing a report that counters fears the industry is losing its ability to innovate. The report emphasizes more than 5,000 drugs are in various clinical phases. Seventy percent are potential first-in-class drugs.
Washington Drug Letter